SP-104 (low-dose naltrexone DR capsules)
Fibromyalgia
PreclinicalDevelopment
Key Facts
About Scilex Holding
Scilex Holding is a revenue-generating biopharma company singularly focused on building a leading franchise in non-opioid pain management. Its strategy combines the commercialization of three approved products—ZTlido®, Elyxyb®, and Gloperba®—with the development of a late-stage pipeline, headlined by SEMDEXA™ (SP-102) for sciatica, which has completed a successful Phase 3 trial. The company aims to address the opioid crisis by providing healthcare providers and patients with effective, non-addictive therapeutic options across a spectrum of pain indications, from neuropathic pain to migraine and gout prophylaxis.
View full company profileTherapeutic Areas
Other Fibromyalgia Drugs
| Drug | Company | Phase |
|---|---|---|
| SP-104 | SCILEX | Preclinical/Phase 1 |
| Sequential Dialysis Technique | Halberd | Discovery |
| Stanza | Swing Therapeutics | Approved |
| Fibromyalgia Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Fibromyalgia Biomarkers | Paradise Genomics | Discovery |
| AXS-14 | Axsome Therapeutics | Phase 3 |